Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.
SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
SI-BONE (Nasdaq:SIBN) reported first quarter 2026 revenue of $52.6 million, up 11.2% year over year, with U.S. revenue of $49.3 million and international revenue of $3.3 million. Gross margin was 79.8% and adjusted EBITDA improved to $2.5 million.
Net loss narrowed to $4.3 million, or $0.10 per share. Cash and equivalents were $144.7 million. SI-BONE raised 2026 revenue guidance to $230–$233 million and increased expected full-year gross margin to about 79%, while maintaining a positive adjusted EBITDA outlook.
SI-BONE (Nasdaq: SIBN) will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on Tuesday, May 12, 2026. Management will host a fireside chat at 8:00 a.m. PT / 11:00 a.m. ET.
Live audio will be available via registration on the conference site and on the company Investors webpage; the webcast will be archived for at least 90 days.
SI-BONE (Nasdaq: SIBN) will report first-quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day.
Investors can register to listen via the provided webcast link and access live audio and a replay from the company’s Investors website; the webcast replay will remain available for at least 90 days.
SI-BONE (Nasdaq: SIBN) reported record Fiscal Year 2025 results with worldwide revenue of $200.9M (up 20.2%) and positive adjusted EBITDA of $8.9M. Fourth quarter revenue was $56.3M (up 15.0%) with positive free cash flow. The company issued 2026 guidance of $228.5M–$232.5M, implying ~14%–16% growth and an expected increase in positive adjusted EBITDA.
Other highlights include a ~79% gross margin, strategic partnership with Smith+Nephew, INTRA Ti launch, expanded physician adoption, and year-end cash of $147.8M.
SI-BONE (Nasdaq: SIBN) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. Management will host a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.
Live audio will stream via the company’s Investors site and a registration link; the webcast will be archived for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN) will report fourth-quarter and full-year 2025 financial results after market close on February 23, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast will be available on the company’s Investors page and archived for at least 90 days.
SI-BONE (Nasdaq: SIBN) reported preliminary, unaudited fourth quarter and full year 2025 results. For Q4 2025 the company expects worldwide revenue of $56.2–$56.3 million (~15% growth) and U.S. revenue of $53.3–$53.4 million (~14% growth). Q4 active U.S. physicians rose to ~1,640 (up 250, ~18%). Cash and cash equivalents were ~$147.7 million, implying net cash generation of ~$2.0 million in the quarter. For fiscal 2025 the company expects worldwide revenue of $200.8–$200.9 million (~20% growth) and U.S. revenue of $190.9–$191.0 million (~21% growth). These figures are preliminary and subject to adjustment pending financial close and audit; final results will be provided on the Q4 2025 earnings call in late February 2026.
SI-BONE (Nasdaq: SIBN) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2, 2025. Management will host a fireside chat at 9:00 a.m. Pacific / 12:00 p.m. Eastern.
Investors can register to listen and access a live audio webcast via the company’s Investors website. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (Nasdaq: SIBN) reported Q3 2025 results with $48.7M worldwide revenue, up 20.6% year-over-year, and $46.4M U.S. revenue, up 21.2%. Gross margin improved to 79.8% (up 75 bps). Net loss narrowed to $4.6M (‑$0.11/share) and adjusted EBITDA was positive $2.3M. The company generated $2.3M of operating cash flow and held $145.7M in cash and equivalents.
Operationally, active U.S. physicians rose 27% to 1,530 and trailing 12-month average revenue per territory grew 16%. Effective Oct 1, 2025, procedures using iFuse TORQ TNT qualify for an NTAP of over $4,100. SI-BONE raised full-year 2025 revenue guidance to $198M–$200M and expects full-year gross margin of ~79.5%.
SI-BONE (Nasdaq: SIBN) reported second-quarter 2025 results with worldwide revenue of $48.6M (+21.7% YoY) and U.S. revenue of $46.4M (+22.8% YoY). Gross margin was 79.8% and adjusted EBITDA turned positive at $1.0M, while net loss improved to $6.2M (‑31.2%). Cash and equivalents totaled $145.5M with $1.1M net cash generated in the quarter. Operationally, active U.S. physicians grew ~25% to 1,440 and trailing 12‑month average revenue per territory rose ~23%. Fiscal 2025 revenue guidance was updated to $195M–$198M (~17%–18% growth) with expected full‑year positive adjusted EBITDA.